TTD | Drug: D0A6DI

Drug General Information
Drug ID	D0A6DI
Former ID	DIB003993
Drug Name	RG-1662
Synonyms	GABA-A agonist (Alzheimer's disease), Roche
Indication	Alzheimer disease [ICD9: 331; ICD10:G30]		Phase 2	[525248]
Company	Roche Holding AG
Target and Pathway
Target(s)	Gamma-aminobutyric-acid receptor alpha-5 subunit	Target Info	Agonist	[551418]
KEGG Pathway	Neuroactive ligand-receptor interaction
	Retrograde endocannabinoid signaling
	GABAergic synapse
	Morphine addiction
	Nicotine addiction
Reactome	Ligand-gated ion channel transport
Reactome	GABA A receptor activation
WikiPathways	Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
WikiPathways	Iron uptake and transport
References
Ref 525248	ClinicalTrials.gov (NCT02484703) A Study of RG1662 in Down Syndrome Among Children 6 to 11 Years of Age.
Ref 551418	RG1662, a Selective GABAA alpha5 Receptor Negative Allosteric Modulator, Increases Gamma Power in Young Adults with Down Syndrome. Neurology April 6, 2015 vol. 84 no. 14.

If you find any error in data or bug in web service, please kindly report it to Dr. Tang and Dr. Mou.

Drug Information